Pharmaceutical Intermediate Storage Conditions: What Buyers Must Know

Why Storage Conditions Matter More Than Most Buyers Assume

A pharmaceutical intermediate sits between raw material and API. It has been purified, characterized, and tested — but it has not been formulated, stabilized with excipients, or sealed in a patient-ready container. That difference matters.

An API in a finished dosage form is protected by packaging, excipients, and a validated shelf life. An intermediate in a foil bag or HDPE drum is protected only by its own chemistry and whatever storage conditions the manufacturer specifies on the COA.

When those conditions are violated — by humidity in a warehouse, sunlight during a dock transfer, or heat during shipping — the intermediate degrades, and the degradation is invisible until downstream yields drop or impurities appear that were not on the original COA.

This guide covers three things:

• The three degradation pathways that improper storage triggers in intermediates
• What the storage-condition field on a COA actually means — and what it does not tell you
• A practical checklist for evaluating storage risk before and after you receive material

Three Degradation Pathways Storage Controls Must Prevent

1. Hydrolysis: The Silent Purity Killer

Water is the most common degradation catalyst for pharmaceutical intermediates. It acts as a reagent — breaking ester, amide, lactam, and anhydride bonds through hydrolysis — and as a plasticizer, lowering the glass transition temperature (Tg) of amorphous solids and increasing molecular mobility, which accelerates diffusion-controlled reactions (Rumondor et al., 2009; Ahlneck & Zografi, 1990).

The practical consequence: a hygroscopic intermediate stored at 75% RH can absorb enough moisture in days to shift its assay by several percentage points — and the change will not appear on an HPLC purity trace if the degradation product is non-UV-absorbing. Only a Karl Fischer water-content test or a full assay comparison against the original COA will reveal it.

How much moisture is too much? There is no universal threshold. The acceptable water content depends on the intermediate’s chemical structure. But as a rule of thumb: if the COA specifies water content ≤ 0.5% by Karl Fischer, and your incoming inspection reads 1.2%, the material has likely already undergone measurable degradation.

2. Photodegradation: Light-Sensitive Intermediates You Didn’t Know About

ICH Q1B requires photostability evaluation for all new drug substances (ICH Q1B, 1998). For intermediates, photostability testing is not always performed — but many intermediates are just as light-sensitive as their parent APIs.

The ICH Q1B confirmatory study standard requires exposure to ≥ 1.2 million lux·hours of visible light and ≥ 200 Wh/m² of UV radiation. Any intermediate that shows significant change under these conditions must be labeled “Protect from light” — and stored in amber containers or opaque packaging.

Intermediates with the following structural features are most at risk: conjugated double bonds, aromatic rings with electron-donating substituents, enone systems, and phenols. If the COA says “Protect from light” and the material arrives in a clear plastic bag, that is a storage failure — even if the COA numbers still look acceptable.

3. Thermal Decomposition: When “Room Temperature” Is Not Enough

ICH Q1A(R2) defines long-term storage conditions for stability testing at 25°C ± 2°C / 60% RH ± 5% RH for Climatic Zones I–II (ICH Q1A(R2), 2003). For intermediates assigned a retest period, the manufacturer must have data showing the material remains within specification at these conditions for the duration of the retest period.

But “room temperature” is not a universal concept. USP <659> defines controlled room temperature (CRT) as 15°C–25°C (revised in 2025 from the previous 20°C–25°C range), with a mean kinetic temperature (MKT) not exceeding 25°C (USP <659>, 2025 revision).

Brief excursions between 15°C and 30°C are permitted, and transient spikes up to 40°C are allowed for no more than 24 hours — provided the MKT stays ≤ 25°C.

For intermediates, the key question is: what happens during those excursions? Some intermediates are thermally robust. Others — particularly those with low melting points (below 80°C), thermally labile functional groups (azides, peroxides, β-lactams), or polymorphic forms — can undergo measurable change in hours, not days.

What the COA Storage Field Actually Means (And What It Doesn’t)

Most intermediate COAs list a storage condition. The most common phrases are:

• “Store at controlled room temperature”— means 15°C–25°C per USP <659>, MKT ≤ 25°C, per the 2025 revision
• “Store in a dry place”— per USP <659>, means average RH ≤ 40% at 20°C, or equivalent water vapor pressure at other temperatures; storage in a container that protects from moisture also qualifies
• “Protect from light”— requires amber or opaque packaging; ICH Q1B confirmatory study standard applies
• “Protect from moisture”— requires sealed moisture-barrier packaging (aluminum foil bags with desiccant, for example)
• “Store refrigerated (2°C–8°C)”— rare for intermediates, applies to temperature-sensitive compounds

What the COA storage field does not tell you:

• Whether the manufacturer performed photostability testing on this intermediate
• Whether the retest period was established at 25°C/60% RH or at 30°C/65% RH (the latter is more stringent and more relevant for tropical-climate buyers)
• The maximum allowable excursion duration or MKT threshold for this specific compound
• What packaging configuration was used for the stability study (the retest period may not apply if you repackage the material)

Temperature Excursions: How to Assess the Real Impact

During shipping, intermediates may experience temperature excursions — short periods outside the specified storage range. The tool for evaluating cumulative thermal stress is mean kinetic temperature (MKT).

MKT is a single calculated temperature that represents the cumulative thermal stress over a time period. It is weighted toward higher temperatures because degradation rates follow Arrhenius kinetics — a few hours at 35°C contribute more to degradation than many hours at 20°C (Kumar & Jha, Saudi Pharm J, 2016).

For CRT storage, USP <659> requires MKT ≤ 25°C. If the MKT of your shipment stays below 25°C, brief excursions above 30°C are generally acceptable — but only if the individual spikes do not exceed 40°C for more than 24 hours.

The problem for intermediate buyers: you usually do not have MKT data. You may have a few temperature logger readings from the shipping container, but not enough to calculate MKT. In that case, assess excursion risk by asking:

• How long was the excursion? (Minutes at a loading dock vs. days in a hot container)
• What was the peak temperature? (30°C is recoverable; 45°C may not be)
• Is the intermediate thermally sensitive? (Check the melting point on the COA — if it’s below 80°C, even moderate excursions can cause physical change)
• Can the supplier provide excursion-impact data? (Some manufacturers have studied this; many have not)

For Climatic Zones III–IV (hot, humid markets), WHO recommends long-term stability testing at 30°C/65% RH (Zone IVa) or 30°C/75% RH (Zone IVb) (WHO Technical Report Series). If your intermediate was only tested at 25°C/60% RH and you are storing it in a warehouse in Southeast Asia, the retest period may not be valid for your conditions.

Four Storage Red Flags on a COA

Before placing an order, check the COA for these four signals:

Red Flag 1: No Storage Condition Listed

If the COA has no storage condition, either the manufacturer did not perform stability testing, or they did not consider it important enough to state. Neither is reassuring. Ask for the stability data that supports the retest period.

Red Flag 2: “Store at Room Temperature” Without the Word “Controlled”

“Room temperature” by itself means only “the temperature prevailing in a working environment” — which could be 30°C in a Chinese factory in July or 18°C in a German warehouse in January. The word “controlled” is what invokes the USP <659> standard (15°C–25°C, MKT ≤ 25°C). Without it, the storage expectation is undefined.

Red Flag 3: “Protect from Moisture” but No Water-Content Data on the COA

If the storage instruction says “Protect from moisture” but the COA has no Karl Fischer water content result, there is a logical gap: the manufacturer knows moisture is a risk but did not test for it. Ask whether water content was tested and whether the result was omitted or simply not performed.

Red Flag 4: Retest Period Based on 25°C/60% RH When Your Warehouse Runs at 30°C/65% RH

The retest period on the COA was established at specific storage conditions. If your actual storage conditions are more extreme — higher temperature, higher humidity, or both — the retest period may need to be shorter. This is especially relevant for buyers in WHO Climatic Zones IVa and IVb. Ask the supplier: “Was the retest period established at 25°C/60% RH or 30°C/65% RH?” For more on retest date evaluation, see our guide on intermediate retest date vs expiry date.

Three Questions to Ask Before Ordering

Before you place an order, ask the supplier these three questions — and document the answers:

Question 1: “What packaging configuration was used for your stability study?”

The retest period applies to the material in the packaging that was tested. If the manufacturer tested in double-sealed aluminum foil bags with desiccant, the retest period may not hold if you receive the material in a single-layer HDPE bag without desiccant.

Packaging matters for moisture-sensitive intermediates — and the difference between foil-laminate and HDPE can change water uptake by an order of magnitude.

Question 2: “Was the retest period established at 25°C/60% RH or 30°C/65% RH?”

This matters for buyers in warmer climates. A 24-month retest period at 25°C/60% RH may correspond to only 12–18 months at 30°C/65% RH, depending on the compound’s degradation kinetics.

If your storage conditions are more demanding than the study conditions, plan for shorter holding times or request stability data at your actual conditions.

Question 3: “Has this intermediate undergone photostability testing per ICH Q1B?”

If the answer is yes, ask for the summary: was significant change observed under the confirmatory conditions (≥ 1.2 million lux·h visible + ≥ 200 Wh/m² UV)? If yes, the material must be stored in light-protective packaging throughout the supply chain.

If the answer is no — photostability was not tested — consider it an unknown risk and store the material in opaque containers as a precaution.

What to Check When You Receive the Material

After the intermediate arrives, run these five checks before releasing it for use:

1. Match the packaging to the COA storage instruction. If the COA says “Protect from moisture” and the material arrives in an unsealed bag, the storage condition has already been violated. If the COA says “Protect from light” and the material is in a clear container, repackage it immediately.
2. Inspect the physical condition. Caking, clumping, color change, or a sticky texture are signs of moisture uptake or thermal stress. A powder that flows freely on the COA date but arrives as a solid block has degraded — physically, if not yet chemically.
3. Check the Karl Fischer water content against the COA. If the original COA reports water content ≤ 0.5% and your incoming test shows 0.8%, the material has absorbed moisture during shipping or storage. The question is whether that moisture has triggered degradation. Compare the assay and impurity profile to the COA to find out.
4. Verify the temperature logger data if available. Calculate MKT from the logger readings. If MKT exceeds 25°C for a CRT-labeled material, document the excursion and assess the impact using the three-question framework above.
5. Confirm the retest date has not passed. If the material’s retest date is close, consider whether your planned usage timeline will exceed it. For guidance on what happens after a retest date, see our article on retest date vs expiry date for pharmaceutical intermediates.

For a broader framework on evaluating the information a COA provides — and what it omits — see our guide on how to read a COA for pharmaceutical intermediates.

And if you are also evaluating shipping risk — the conditions between the supplier’s warehouse and yours — our article on shipping pharmaceutical intermediates from China covers the logistics side of temperature and moisture control during transit.

FAQ: Pharmaceutical Intermediate Storage Conditions

Do pharmaceutical intermediates need cold-chain storage?

Most intermediates do not require refrigeration. The majority are stored at controlled room temperature (15°C–25°C per USP <659>). However, a small number of temperature-sensitive intermediates — particularly those with low melting points or thermally labile functional groups — may require cool storage (8°C–15°C) or refrigeration (2°C–8°C). The COA storage field will specify this if applicable.

What does “Store in a dry place” mean on a COA?

Per USP <659>, “dry place” means a location with average relative humidity ≤ 40% at 20°C, or equivalent water vapor pressure at other temperatures. Storage in a container that protects from moisture (sealed foil bags, HDPE drums with tight lids) also qualifies as a “dry place” regardless of ambient humidity.

How long can an intermediate tolerate a temperature excursion?

USP <659> permits excursions between 15°C and 30°C for CRT-stored materials, and transient spikes up to 40°C for no more than 24 hours, provided the mean kinetic temperature (MKT) stays ≤ 25°C. For excursions beyond these limits, the impact depends on the compound’s thermal stability — which must be evaluated on a case-by-case basis using available stability data or testing.

Can I repackage an intermediate without affecting its retest period?

Possibly, but not guaranteed. The retest period was established for the material in the packaging used during stability testing. Repackaging from a moisture-barrier container (foil-laminate bag) into a less protective container (HDPE bag without desiccant) may accelerate moisture uptake and reduce the effective holding time. If repackaging is necessary, use packaging with equivalent or better barrier properties, and monitor water content at regular intervals.

What if my warehouse is in WHO Climatic Zone IV (hot and humid)?

If the intermediate’s stability data were generated only at 25°C/60% RH (ICH Zone II conditions), the stated retest period may not be valid at 30°C/65% RH (Zone IVa) or 30°C/75% RH (Zone IVb). Request stability data at your actual conditions, or plan for a shorter retest period and more frequent monitoring. WHO TRS guidance recommends that stability studies for global distribution include Zone IV conditions.

References

1. ICH Q1A(R2). Stability Testing of New Drug Substances and Products.International Council for Harmonisation, 2003. Full text (EMA)
2. ICH Q1B. Photostability Testing of New Drug Substances and Products.International Council for Harmonisation, 1998. ICH Quality Guidelines page
3. USP <659>. Packaging and Storage Requirements.United States Pharmacopeia, 2025 Revision. Controlled room temperature definition updated from 20°C–25°C to 15°C–25°C.
4. WHO Technical Report Series. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products.WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO TRS publications
5. Kumar N, Jha A. “Temperature excursion management: A novel approach of quality system in pharmaceutical industry.” Saudi Pharm J.2016;25(2):176–183. PMC5355558
6. Rumondor AC, Stanford LA, Taylor LS. “Effect of moisture on the amorphous-to-crystalline transformation of intact and milled spray-dried amorphous solid dispersions.” Int J Pharm.2009;380(1–2):67–76. ScienceDirect
7. Ahlneck C, Zografi G. “The molecular basis of moisture effects on the physical and chemical stability of amorphous pharmaceuticals.” Int J Pharm.1990;62(2–3):87–95.